Randomized phase 2b dose-escalation trial of stem cell therapy with laromestrocel for aging frailty

Journal:
Cell Stem Cell
Published:
Affiliations:
17
Authors:
25
Institutions Authors Share
Longeveron Inc., United States of America (USA)
10.500000
10.500000
0.42
Miami VA Healthcare System, United States of America (USA)
2.000000
0.08
Advanced Research for Health Improvement, United States of America (USA)
1.000000
0.04
Clinical Research of South Florida, United States of America (USA)
1.000000
0.04
Panax Clinical Research, United States of America (USA)
1.000000
0.04
Vista Health Research, United States of America (USA)
1.000000
0.04
Clinical Physiology Associates, United States of America (USA)
1.000000
0.04
Johns Hopkins University (JHU), United States of America (USA)
1.000000
0.04
National Center for Geriatrics and Gerontology Hospital, Japan
1.000000
0.04
University of Pittsburgh (Pitt), United States of America (USA)
1.000000
0.04
Pharma Data Associates, United States of America (USA)
1.000000
0.04
Provonix, United States of America (USA)
1.000000
0.04
Memorial Healthcare System (MHS), United States of America (USA)
0.500000
0.02
Florida Atlantic University (FAU), United States of America (USA)
0.500000
0.02
The University of Texas Health Science Center at San Antonio (UT Health San Antonio), United States of America (USA)
0.500000
0.02
South Texas Veterans Health Care System (STVHCS), United States of America (USA)
0.500000
0.02
The University of Miami Miller School of Medicine, UM, United States of America (USA)
0.500000
0.02